33 results about "Soft tissues tumors" patented technology

The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial CDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of treating a patient with soft tissue tumor comprising the step of exposing the patient to the immunotoxin of the invention.

An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.

Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and / or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation.In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.

The invention belongs to the technical field of formulae of homology of medicine and food and new resource foods, and in particular provides a medical formula food, a specific medical formula food or a non-specific medical formula food for patients with soft tissue tumors. The formula food is processed by following the requirements of general rule of formula food for special medical purpose, combining the physical constitution of the patients with soft tissue tumors, reasonably matching a plurality of traditional Chinese medicines of homology of medicine and food according to the essence theory of traditional Chinese medicine, and mixing a plurality of edible and medical traditional Chinese medicine extract essence extracted by prehydrolysis SBE technology, a plurality of microcapsuled probiotics and biological enzymolysis extracted short peptides, prebiotics, amino acids, carbohydrates, as well as health-care grease, a plurality of vitamins and mineral substances. The medical formula food provided in the invention can meet the nutritive requirement of the patients with soft tissue tumor as a single nutritive source, and has the efficacy of clearing away heat and toxic materials, eliminating swelling, removing stasis, promoting blood circulation to remove blood stasis, resolving hard lump, benefiting qi and nourishing blood and enhancing immunity.

The invention discloses a dual slow release biological preparation for tumor local ablation therapy, which comprises temperature sensing type gel, ricin, noradrenalin and poison microsphere carried with cobra venom cell and is made by the temperature sensing type gel packaging the noradrenalin, the ricin and the poison microsphere carried with cobra venom cell. The concentration of the temperature sensing type gel is 15-45, the temperature sensing type gel with concentration of 15-4501AF3450er ml contains the noradrenalin 10-100 mu g, the ricin 0. 1-1 mu g, the poison microsphere carried withcobra venom cell 2-20 mu g. The invention can be injected into the a nude mice tumor tissue of human hepatocellular carcinoma or can be injected with rabbit home position liver tumor VX2 under ultrasonic guiding in experiment, the invention has obvious anti-tumor effect, can be applied for local ablation therapy of human liver, kidney, pancreas, spleen, prostate gland, uterus, ovary, retroperitoneal and superficial soft tissue tumors under ultrasonic wave or CT guiding.

The invention belongs to the field of biomedical materials, and in particular relates to the preparation and application of a tissue repair-promoting hydrogel with both anti-tumor and antibacterial functions. The preparation method of the tissue-repairing hydrogel of the present invention mainly comprises: firstly, using arginine to modify chitosan, and then physically compounding with polydopamine and nano-hydroxyapatite to form arginine-modified chitosan ‑polydopamine / nano hydroxyapatite solution, and finally the solution is cross-linked with a hydrophilic molecule (OHC‑PEG‑CHO) with both ends being aldehyde groups to form a hydrogel. The hydrogel for promoting tissue repair constructed by the invention has a three-dimensional network structure and can inhibit the growth of tumor cells and bacteria, but has no obvious inhibition on the growth of normal cells. The use of hydrogel for defect filling or skin wound repair after skin or soft tissue tumor resection can achieve efficient antibacterial, promote tissue repair, prevent scar tissue formation, and inhibit local tumor recurrence, and has a good clinical application prospect .

Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and / or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

The invention discloses a preparation method of a tumor cell vaccine targeting CAFs, which belongs to the technical field of biomedicine. The method is to infect tumor cells with a lentiviral packaging plasmid to obtain a stable expression strain, and then inactivate the preparation method; the invention also discloses The application of the vaccine prepared by the above method; the present invention is based on a new preparation method, the prepared vaccine can express antigen more stably, the response rate of immunotherapy is higher, the effect is better and more stable, and the obtained vaccine is broad-spectrum Vaccine can treat more than 90% of epithelial tumors, some soft tissue tumors and melanoma; in addition, this vaccine can also enhance the radiosensitivity of tumors, and it can achieve better results when used in combination with radiotherapy, especially ablative radiotherapy , and can improve the fibrosis caused by radiotherapy and reduce the side effects of radiotherapy.